Vinorelbine

Vinca Alkaloid — ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS

Key facts

Vinorelbine is an ofp drug in the Vinca Alkaloid class catalogued in DrugCentral. It was first approved by the FDA in 1994. DrugCentral lists 3 molecular targets, including TACR2, CYP3A4 and TUBB|TUBB1|TUBB2A|TUBB2B|TUBB3|TUBB4A|TUBB4B|TUBB6|TUBB8. Recorded indications include Non-small cell lung cancer.

• Approval status: ofp (first approved 1994 by the FDA).
• Drug class: Vinca Alkaloid.
• Molecular targets: TACR2, CYP3A4 and TUBB|TUBB1|TUBB2A|TUBB2B|TUBB3|TUBB4A|TUBB4B|TUBB6|TUBB8 (3 listed in DrugCentral).
• Indications: Non-small cell lung cancer.
• ATC code: L01CA04 (Vinca alkaloids and analogues).
• Molecular formula: C45H54N4O8; molecular weight 778.95 g/mol.

Indications & contraindications

Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).

Indications (1)

• Non-small cell lung cancer

Off-label uses (4)

• Kaposi's sarcoma
• Metastatic Breast Carcinoma
• Neoplasm of endometrium
• Small cell carcinoma of lung

Contraindications (14)

• Bone marrow depression
• Breastfeeding (mother)
• Disorder of lung
• Gastrointestinal obstruction
• Gastrointestinal perforation
• Hepatic failure
• Hepatic Metastases
• Infectious disease
• Interstitial pneumonia
• Intestinal Ischemic Necrosis
• Intestinal obstruction
• Leukopenia
• Pregnancy, function
• Severe Granulocytopenia

Mechanism & targets

• Established pharmacologic class: Vinca Alkaloid

Molecular targets (3)

Target	Gene	Action	Activity
Substance-K receptor	TACR2	unknown	Ki 6.27
Cytochrome P450 3A4	CYP3A4	unknown	IC50 6.00
Tubulin beta	TUBB|TUBB1|TUBB2A|TUBB2B|TUBB3|TUBB4A|TUBB4B|TUBB6|TUBB8	inhibitor	—

Regulatory approvals (1)

Date	Agency	Marketed as	Applicant	Orphan
1994-12-23	FDA	—	PIERRE FABRE

ATC classification

ATC code	Therapeutic hierarchy
L01CA04	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS › ANTINEOPLASTIC AGENTS › PLANT ALKALOIDS AND OTHER NATURAL PRODUCTS › Vinca alkaloids and analogues

Reported adverse-event signals

Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.

MedDRA term	LLR
Disease progression	1281.9
Malignant neoplasm progression	1121.3
Neutropenia	736.0
Metastases to bone	547.3
Metastases to liver	497.6
Palmar-plantar erythrodysaesthesia syndrome	474.0
Breast cancer metastatic	462.7
Metastases to central nervous system	423.2
Metastases to lung	412.8
Metastases to lymph nodes	402.2
Neoplasm progression	342.6
Febrile neutropenia	338.5

Chemical structure

Full physicochemical, ADMET and 3D-structure analysis of Vinorelbine is on its molecule page.

• Molecular formula: C₄₅H₅₄N₄O₈
• Molecular weight: 778.95 g/mol
• CAS number: 71486-22-1
• InChIKey: GBABOYUKABKIAF-IELIFDKJSA-N
• PubChem CID: 5311497

CCC1=C[C@@H]2C[N@](C1)CC1=C(NC3=C1C=CC=C3)[C@@](C2)(C(=O)OC)C1=CC2=C(C=C1OC)N(C)[C@@H]1[C@]22CCN3CC=C[C@](CC)([C@@H]23)[C@@H](OC(C)=O)[C@]1(O)C(=O)OC

Frequently asked questions

Answers are generated from the structured data on this page, not written by hand.

What is Vinorelbine used for?

DrugCentral lists the following indications for Vinorelbine: Non-small cell lung cancer.

How does Vinorelbine work?

Its molecular targets in DrugCentral include TACR2, CYP3A4 and TUBB|TUBB1|TUBB2A|TUBB2B|TUBB3|TUBB4A|TUBB4B|TUBB6|TUBB8 (inhibitor).

When was Vinorelbine first approved?

Vinorelbine was first approved by the FDA in 1994.

What drug class does Vinorelbine belong to?

Vinorelbine is in the Vinca Alkaloid class.

What is the chemical formula of Vinorelbine?

Vinorelbine has the molecular formula C45H54N4O8 and a molecular weight of 778.95 g/mol.

Sources

• DrugCentral drug card 2827 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
• ChEMBL CHEMBL538943 — compound record and bioactivity
• PubChem CID 5311497 — chemical identifiers
• DrugBank DB00361 — drug record
• FDA UNII Q6C979R91Y — substance identity
• DailyMed: FDA labels for Vinorelbine — current prescribing information (label search)
• UniProt P21452 (TACR2) — target protein
• UniProt P08684 (CYP3A4) — target protein
• FDA Adverse Event Reporting System (openFDA FAERS) — adverse-event signals, as aggregated by DrugCentral

How this page is built: methodology · editorial policy & corrections.